Ampio Pharmaceuticals Inc (NYSEAMERICAN:AMPE) was the target of a large increase in short interest in the month of November. As of November 30th, there was short interest totalling 8,028,174 shares, an increase of 26.3% from the November 15th total of 6,358,596 shares. Based on an average daily volume of 1,901,799 shares, the days-to-cover ratio is presently 4.2 days. Currently, 11.7% of the company’s shares are sold short.

Separately, ValuEngine upgraded Ampio Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Wednesday, October 11th.

Shares of Ampio Pharmaceuticals (NYSEAMERICAN:AMPE) traded up $0.05 during trading on Monday, reaching $1.61. The company had a trading volume of 599,608 shares, compared to its average volume of 527,417. Ampio Pharmaceuticals has a 12 month low of $0.38 and a 12 month high of $2.20.

COPYRIGHT VIOLATION WARNING: This news story was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another domain, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2017/12/11/ampio-pharmaceuticals-inc-ampe-short-interest-update.html.

About Ampio Pharmaceuticals

Ampio Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused primarily on the development of therapies to treat prevalent inflammatory conditions for which there are limited treatment options. The Company’s two lead product candidates in development are Ampion for osteoarthritis of the knee and Optina for diabetic macular edema.

Receive News & Ratings for Ampio Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ampio Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.